Orchestra BioMed posts investor deck spotlighting pivotal-stage AVIM hypertension therapy and Virtue sirolimus balloon program

Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc.

OBIO

0.00
  • Orchestra BioMed highlighted two pivotal-stage cardiovascular programs, led by its AVIM Therapy pacing approach for hypertension and hypertensive heart disease.
  • BACKBEAT global pivotal trial: up to 316 patients across 130 sites; enrollment completion targeted by end of Q3 2026.
  • Primary endpoint data targeted for a late-breaking presentation in Q2 2027; FDA marketing application planned if endpoints are met.
  • Medtronic collaboration terms include exclusive global commercial rights for the initial HTN plus pacemaker market; revenue share of $500-$1,600 per AVIM-enabled device.
  • Virtue SAB sirolimus delivery balloon: pivotal trial initiated in Q4 2025; enrollment completion targeted in 2027; coronary and peripheral opportunities estimated at more than $10 billion and more than $7.5 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.